Veracyte (VCYT) Shares Rise 1.58 % on Wednesday 21 Oct 2026
Veracyte (VCYT) closed 1.58 % higher during a 24‑hour trading period ending at 04:49 AM Central Europe on Wednesday 21 Oct 2026. The current trading price is USD 44.79 on major exchanges.
Market Overview
| Item | Value |
|---|---|
| Market Capitalisation | USD 3.5 bn |
| Shares Outstanding | 80.5 mn |
| 24‑Hour Volume | USD 31.8 mn |
| 52‑Week High | USD 60.91 (30 Jun 2026) |
| 52‑Week Low | USD 29.46 (27 Mar 2026) |
| 200‑Day Simple Moving Average | USD 42.60 |
| Month‑End Change | +5.49 % |
Recent Performance
In the last 24 hours, Veracyte traded up 1.58 %. Compared with the previous month‑end, the share price has increased by 5.49 %. The 200‑day simple moving average sits at USD 42.60, indicating the current price of USD 44.79 is above the recent trend line.
Related Stock Movements
| Company | Symbol | 24‑Hour Change | Current Price | Market Cap | P/E Ratio |
|---|---|---|---|---|---|
| Siteone Landscape Supply | SITE | -0.64 % | USD 96.58 | USD 4.1 bn | 26.08 |
| Howard Hughes | HHH | -2.90 % | USD 69.11 | USD 4.1 bn | 13.98 |
| Tutor Perini | TPC | +0.80 % | USD 77.90 | USD 4.1 bn | 33.23 |
| Tenable | TENB | +4.65 % | USD 38.98 | USD 4.1 bn | 641.28 |
| Icu Medical | ICUI | -1.07 % | USD 161.08 | USD 4.1 bn | 135.77 |
Company Profile
Veracyte, Inc. is a biotechnology firm headquartered in South San Francisco, California. The company develops molecular diagnostic tests for oncology, focusing on molecular cytology to enhance the accuracy of cytology samples. Products are marketed to healthcare providers and molecular diagnostic companies within the United States. Veracyte is listed on the Nasdaq stock exchange and completed its initial public offering on 30 Oct 2013. The company’s website is www.veracyte.com .
